Selective Janus Kinase Inhibitors for Autoimmune Disease
Researchers at Purdue University have developed a series of molecules, based on a new JAK inhibitor scaffold, that display selective inhibition for different members of the Janus kinase family. One particular compound, designed for high potency and stability, exhibits very good activity and selectivity against JAK1, with 3.3 nM activity and 10 fold and 30 fold selectivity versus JAK2 and JAK3, respectively. These new inhibitors promise to give relief to sufferers of psoriasis, myelofibrosis, rheumatoid arthritis, and other autoimmune diseases with a reduction in side effects compared to current therapies.
Reduce side effectsAllow for more options in treatments
Treatment of autoimmune diseases
Mark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology
United States
None
美國
